Personalized NK Cell Therapy in CBT
Phase 2
100
about 11 years
15–80
1 site in TX
About this study
This trial is testing personalized natural killer (NK) cell therapy to see if it helps patients with certain types of blood cancers or bone marrow disorders after they have received chemotherapy and a cord blood transplant. The goal is to use the patient's own NK cells, which are immune cells that can kill cancer cells, to reduce the risk of complications from the transplant.
Based on ClinicalTrials.gov records.
What participants do
- 1.Laboratory Biomarker Analysis
- 2.Receive Allogeneic Natural Killer Cell Line NK-92
- 3.Receive Anti-Thymocyte Globulin
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
busulfan, clofarabine, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), melphalan, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
injection, intravenous, infusion, injection (Injection)
Primary: Progression free survival (PFS) time in C1 patients, Progression free survival (PFS) time in C2C2 patients
Secondary: Overall survival time
radiation
Oncology